SPECTRUM PHARMACEUTICALS, INC. : Spectrum Pharmaceuticals …4-tradersThe ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the combined effect of a targeted bio…
Spectrum Pharmaceuticals Announces Publication in the Journal of Clinical …MarketWatch (press release)The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the…
Unique cell type in multiple sclerosisUPI.comClinical trials have shown daclizumab appears to help quiet the autoimmune response in MS patients, but its precise effects on the legions of cells that make up the immune system are not fully understood, Be…
Researchers implicate unique cell type in multiple sclerosisMedical XpressOngoing clinical trials have shown that daclizumab appears to help quiet the autoimmune response in MS patients, but its precise effects on the legions of cells that make up the …
Unique Cell Type in Implicated in Multiple SclerosisScience Daily (press release)The new study, published in Science Translational Medicine, shows that one effect of daclizumab is to thin the ranks of lymphoid tissue inducer (LTi) cells. These cells ar…
Cell Therapeutics, Inc. (CTI) Readies Pixuvri® European Launch and Start of …Sacramento BeeThe European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized con…
Cell Therapeutics, Inc. (CTI) Readies Pixuvri® European Launch and Start of …MSN MoneyThe European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized controll…
Cell Therapeutics, Inc. (CTI) Readies Pixuvri® European Launch and Start of …MarketWatch (press release)The European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing r…
Rituxan Effective in Refractory RAMedPage TodayPatients with rheumatoid arthritis who fail on treatment with a tumor necrosis factor (TNF) inhibitor may have a better response if they switch to rituximab (Rituxan) rather than trying a second TNF blocke…
Rituximab aids remission in idiopathic membranous nephropathyNews-Medical.netBy Andrew Czyzewski, MedWire Reporter. Rituximab achieves good rates of remission in patients with persistent idiopathic membranous nephropathy (IMN), with few serious adverse…